Opko健康 OPK 深 沪
等待开盘 07-08 09:30:00 美东时间
1.49
-0.010
-0.67%
华盛通- 最 高1.51
- 今 开1.49
- 成交量 212.91万股
- 最 低 1.4601
- 昨 收 1.50
- 总市值 11.25亿
- 52周最高 1.6051
- 市盈率 静 --
- 换手率 0.28%
- 52周最低 0.9769
- 委 比 33.16%
- 总股本 7.55亿
- 历史最高 19.20
- 量 比 0.70
- 振 幅 3.33%
- 历史最低 0.8516
- 每 手 1
- 风险率 0.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Bio Reports Preclinical Results For Oral Peptide Programs EB612 And EB618, Advancing Toward Clinical Development
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for o...
06-16 20:44
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
OPKO Biologics presented preclinical data for OPK8801001, a novel long-acting hGH receptor antagonist for acromegaly, at ENDO 2026. The data showed robust, dose-dependent suppression of IGF-1 and superior potency compared to Pegvisomant. OPK880101 could offer a weekly treatment option, reducing the burden of daily therapy. Acromegaly, caused by excess growth hormone, leads to serious health issues. OPKO Biologics, a clinical-stage company, is adv...
06-15 12:00
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio Ltd. reported Q1 2026 financial results and business updates, highlighting progress in its oral peptide therapeutics pipeline. Key developments include the submission of a streamlined Phase 3 protocol for EB613, an oral anabolic tablet for postmenopausal osteoporosis, and expanded collaboration with OPKO for EB612, an oral long-acting PTH tablet for hypoparathyroidism. Additionally, data for EB618, an oral dual GLP-1/glucagon tablet fo...
05-08 20:05
Opko Health shares are trading lower after the company reported worse-than-expected Q1 sales results and issued Q2 sales guidance below estimates.
Opko Health shares are trading lower after the company reported worse-than-expe...
04-30 00:52
Barrington Research Downgrades OPKO Health to Market Perform
Barrington Research analyst Michael Petusky downgrades OPKO Health (NASDAQ:OPK) from Outperform to Market Perform.
04-29 20:57
OPKO Health Q1 2026 Earnings Call: Complete Transcript
OPKO Health (NASDAQ:OPK) reported first-quarter financial results on Tuesday. T...
04-29 16:34
OPKO Health Sees Q2 Sales $127.000M-$132.000M vs $136.329M Est
OPKO Health (NASDAQ:OPK) sees Q2 sales of $127.000 million-$132.000 million vs $136.329 million analyst estimate.
04-29 04:08
Earnings Scheduled For April 28, 2026
Companies Reporting Before The Bell • LGI Homes (NASDAQ:LGIH) is likely to repo...
04-28 19:11
